Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

mitted to continuing to invest in this promising technology and to bring it to market as soon as possible."

The ABSORB trial reinforces Abbott's commitment to research and develop innovative devices in vascular care. Abbott's robust vascular research program includes clinical trials in peripheral artery disease, carotid artery disease, and coronary artery disease. Key products in the vascular pipeline include: the Omnilink Elite(TM) Peripheral Stent System; the EMBOSHIELD NAV6(TM) Embolic Protection System for carotid stenting; and the XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, which builds upon the proven performance of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System.

Onmilink Elite, EMBOSHIELD NAV6 and XIENCE PRIME are investigational devices and are not available for sale.

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label), two-phase study designed to enroll approximately 110 patients in Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days; six, nine, 12 and 18 months; and two years, with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioabsorbable drug eluting stent, including successful deployment of the system. Other key endpoints of the study include imaging assessments by angiography, intravascular ultrasound (IVUS), optical coherence tomography (OCT), and other state-of-the-art invasive and non-invasive imaging modalities at six months, one year and two years.

Abbott's bioabsorbable drug eluting device delivers everolimus, a drug that inhibits tissue proliferation. The device props open and supports a narrowed blood vessel until the vessel heals, restoring blood flow, and is abs
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... CITY, Calif. , July 24, 2014   ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today confirmed the PDUFA date for Zalviso ... learned that a rumor circulated online stating the Food ... July 24, 2014 there has been no notification to ...
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... Amgen (NASDAQ: AMGN ) today announced ... Tuesday, July 29, 2014, after the close of the U.S. ... call with the investment community at 2 p.m. PT. Participating ... Bradway , chairman and chief executive officer, and other members ... the conference call will be simultaneously broadcast over the Internet ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/25/2014)... July 25, 2014 Newyorktermlifeinsurance.org has ... life insurance plans and traditional policies. , The ... clients make between no medical exam life insurance plans ... types of life insurance plans to provide a simple ... life insurance plans can now be purchased online. Although ...
(Date:7/25/2014)... July 25, 2014 CarePoint Health is ... Edward Boylan, has joined our network, CarePoint Health Medical ... Hundreds of highly skilled and experienced physicians comprise CarePoint ... and practices in Hudson County, representing a wide range ... to provide the highest quality care to patients and ...
(Date:7/25/2014)... Rockville Centre, NY (PRWEB) July 25, 2014 ... national personal injury law firm with over 25 ... of harm stemming from dangerous prescription drugs, announces ... , to offer information to those who believe ... Xarelto. , The site offers valuable information ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 ... Outlook to 2020” provides company shares and distribution ... and global corporate-level profiles of the key market ... to the Laryngoscopes market wherever available. , The ... market forecast models. Rsearcher uses epidemiology and capital ...
(Date:7/25/2014)... Although cervical cancers are declining in the United States ... are increasing, a new study indicates. HPV-related cancers ... and tonsils have increased over the past 35 years, ... Canadian researchers report. "The increases in the incidence ... anal cancer among younger women are disturbing, because there ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2
... In a study of 14 adults with histories of ... not appear// to have effects that indicate potential for ... report in the October issue of Archives of General ... to 15 percent of adults regularly experience chronic insomnia, ...
... the time, they are nothing but a cosmetic nuisance. ... dividing abnormally to form a deadly form of skin ... this year will be diagnosed with melanoma at some ... percent of all melanomas begin in a mole. They ...
... of Nutrition in its current issue (October) has published ... Cookies TM can not only lower cholesterol levels but ... This would substantially curtail the risk of cardiac disease. ... purposes taken from the common fleawort, proven to be ...
... Health and Clinical Excellence (Nice) has planned new guidelines ... (porous bones) are at higher risk of fractures. The ... fragile bones. ,Post menopausal women at any ... wants to execute guidelines according to which, only women ...
... World Action on Salt and Health has been launched today ... 2.5 million deaths a year.// ,194 medical experts in ... companies into reducing dietary salt intake to prevent high blood ... a World Health Organisation summit in Paris to discuss the ...
... research proposes that the drug used to treat wet age-related ... vision in some people. // ,Wet AMD is the ... can be regained to some extent in people with a ... drug Lucentis. ,The study was published in the ...
Cached Medicine News:Health News:New Sleep Medication not Effective for Treating Abuse or Cognitive Impairment 2Health News:New Sleep Medication not Effective for Treating Abuse or Cognitive Impairment 3Health News:Why Don’t All Moles Progress to Melanoma 2Health News:Why Don’t All Moles Progress to Melanoma 3Health News:Chocolate Chip Cookies to Keep Cholesterol at Bay 2Health News:Food Makers Pressurized to Reduce Salt 2Health News:Vision restoration with a drug for macular degeneration 2
The EK-H Series offer 10 selectable units of measure...
Digital Thermometer & High-Low Temp Alarm, -50C to +90C...
Thermometer for Round Water Bath...
... Digital Thermostat and Digital Display. , Exterior300 ... , Interiorwhite anodized aluminum with 300 ... refrigeration (134A). , Temperature range 0C ... doors. , Foamed-in-place polyurethane high density ...
Medicine Products: